Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses

Journal of Veterinary Pharmacology and Therapeutics

Volumn 28, Issue 4, 2005, Pages 355-361

  Orsini, J A ^a,c   Moate, P J ^a   Boston, R C ^a   Norman, T ^b   Engiles, J ^a   Benson, C E ^a   Poppenga, R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; IMIPENEM; PRIMAXIM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; DRUG SENSITIVITY; DRUG SYNOVIAL FLUID LEVEL; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; KIDNEY CLEARANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CILASTATIN; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HORSES; IMIPENEM; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; SYNOVIAL FLUID;

EQUIDAE;

EID: 23244452745     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2005.00667.x     Document Type: Article

References (24)

1. Barker, C.W., Zhang, W., Sanchez, S. et al. (2003) Pharmacokinetics of imipenem in dogs. American Journal of Veterinary Research, 64, 694-699.
2. Belzberg, H., Zhu, H., Cornwell, EE et al. (2004) Imipenem levels are not predictable in the critically ill patient. Journal of Trauma, 56, 111-117.
3. Bentley, A.P., Barton, M.H., Lee, M.D. et al. (2002) Antimicrobial- induced endotoxin and cytokine activity in an in vitro model of septicemia in foals. American Journal of Veterinary Research, 63, 660-668.
4. Dailly, E., Kergueris, M.F., Pannier, M. et al. (2003) Population pharmacokinetics of imipenem in burn patients. Fundamental & Clinical Pharmacology, 17, 645-650.
5. Edwards, J.R. & Turner, P.J. (1995) Laboratory data which differentiate meropenem and imipenem. Scandinavian Journal of Infectious Diseases, 96(Suppl.), 5-10.
6. Jacks, S.S., Giguere, S. & Nguyen, A. (2003) In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. Antimicrobial Agents & Chemotherapy, 47, 1742-1745.
7. Kahan, F.M., Kropp, H., Sundelof, J.G. et al. (1983). Thienamycin: development of imipenem-cilastatin. Journal of Antimicrobial Chemotherapy, 12(Suppl. D), 1-35.
8. Limosin, A., Dupuis, A., Lamarche, I. et al. (2004) Pharmacokinetic- pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia. Journal of Antimicrobial Chemotherapy, 54, 187-192.
9. Linke, E.G., Henry, J.B. & Statland, B.E. (1979) Clinical Diagnosis and Laboratory Methods, 16th edn. pp. 53-76. W. B. Saunders Co., Philadelphia, PA, USA.
10. Mouton, J.W., Touw, D.J., Horrevorts, A.M. et al. (2000) Comparative pharmacokinetics of the carbapenems. Clinical Pharmacokinetics, 39, 185-201.
11. Murray, P.R., Baron, E.J., Pfaller, M.A. et al. (2001) Manual of Clinical Microbiology. Vol 9. pp 1535-1536. ASM Press. Washington. DC, USA.
12. National Committee for Clinical Laboratory Standards (NCCLS) (2002) Performance Standards for Antimicrobial Susceptibility Testing. M100 Series; Latest Annual Edition.
13. Navas, D., Caillon, J., Gras-Le Guen, C. et al. (2004) Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas caeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. Journal of Antimicrobial Chemotherapy, 54, 767-771.
14. Norrby, S.R., Bjornegard, B., Ferber, F. et al. (1983) Pharmacokinetics of imipenem in healthy volunteers. Journal of Antimicrobial Chemotherapy, 12(Suppl. D), 109-124.
15. Orsini, J.A., Moate, P.J., Norman, T. et al. (2004) Cefotaxime kinetics in plasma and synovial fluid following intravenous administration in horses. Journal of Veterinary Pharmacology Therapy 27, 293-298.
16. Prescott, J.F., Hanna, W.J.B., Reid-Smith, R. et al. (2002) Antimicrobial drug use and resistance in dogs. Canadian Veterinary Journal, 43, 107-116.
17. Rorvik, A.M. (1995) Methods and errors in measurements of synovial fluid volume in stifles with low volume and high viscosity synovial fluid. An experimental study in goats. Acta Veterinaria Scandinavica, 36, 213-222.
18. Seol, B., Naglic, T., Madic, J. et al. (2002) in vitro antimicrobial susceptibility of 183 Pseudomonas aeruginosa strains isolated from dogs to selected antipseudomonal agents. Journal of Veterinary Medicine, Series B, 49, 188-192.
19. Soki, J., Fodor, E., Urban, E. et al. (2002) Isolation and characterization of an imipenem-resistant Bacteroides fragilis strain from a prostate abscess in a dog. (Letter to the Editor) Veterinary Microbiology, 84, 187-190.
20. Soma, L.R., Uboh, C.E., Rudy, J.A. & Perkowski, S.Z. (1995) Plasma and synovial fluid kinetics, disposition and urinary excretion of naproxen in the horse. American Journal of Veterinary Research, 56, 1075-1080.
21. Stefanovski, D., Moate, P.J. & Boston, R.C. (2003) WinSAAM: A windows based compartmental modeling system. Metabolism, 52, 1153-1166.
22. Swanston, D.J., DeAngelis, C., Smith, I.L. & Schentag, J.J. (1986) Degradation kinetics of Imipenem in normal saline and in human serum. Antimicrobial Agents and Chemotherapy 29, 936-937.
23. Tegeder, I., Schmidtko, A., Brautigam, L. et al. (2002) Tissue distribution of imipenem in critically ill patients. Clinical Pharmacology & Therapeutics, 71, 325-333.
24. Wastney, M.E., Patterson, B.H., Linares, O.A. et al. (1999) Investigating Biological Systems Using Modeling-Strategies and Software. Academic Press, San Diego.